Compare Merck & Co., Inc. (MRK) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NRG Energy Inc — how do they compare? Merck & Co., Inc. trades at $133.3 (market cap $321.77B), while NRG Energy Inc trades at $121.07 (market cap $24.83B). The key difference: Merck & Co., Inc. is far larger — about 13× NRG Energy Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | NRG | |
|---|---|---|
Market Cap | $321.77B | $24.83B |
Sector | Health | Utilities |
52-Week High | $131.84 | $184.03 |
52-Week Low | $77.60 | $117.04 |
Enterprise Value | $368.53B | $48.79B |
Dividend Yield | 2.61% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
NRG Energy trades at $120.97, up 1.73% today, with a bearish technical signal despite oversold RSI levels near support at $119. The company reported Q2 2026 EPS of $1.49, missing estimates of $1.69, but revenue grew 11% year-over-year, driven by cost controls and a strategic 1.2 GW Texas data-center power project. Fundamentals show a P/E of 30.76 and ROE of 26.77%, though net margin is thin at 2.56%.
Outlook is mixed: analyst consensus is bullish with a $207.83 price target (69% buy ratings), citing growth from data-center demand, but risks include rising interest costs, high leverage (debt-to-assets at 56.42% in 2025), and earnings misses. The stock offers a 1.6% dividend yield, but investors face volatility from execution risks in expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
